RL-007
Cognitive Impairment Associated with Schizophrenia (CIAS)
Phase 2Active
Key Facts
Indication
Cognitive Impairment Associated with Schizophrenia (CIAS)
Phase
Phase 2
Status
Active
Company
About Recognify Life Sciences
Recognify Life Sciences is a San Diego-based biotech, founded in 2020, developing RL-007, a novel GABAB/cholinergic modulator for cognitive impairment. The company is a subsidiary of atai Life Sciences and is led by a team with deep CNS and pharmaceutical development expertise. Its primary focus is advancing RL-007 into Phase 2 trials for CIAS, addressing a significant unmet need with no currently approved therapies.
View full company profileTherapeutic Areas
Other Cognitive Impairment Associated with Schizophrenia (CIAS) Drugs
| Drug | Company | Phase |
|---|---|---|
| ALTO-101 | Alto Neuroscience | Phase 2b |